Jefferies Group’s Sage Therapeutics SAGE Stock Holding History

Jefferies Group’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.48M	Buy	37,800 +12,800	+51%	+$495K	0.01%	694
2022 Q2	$808K	Hold	25,000	–	–	0.01%	858
2022 Q1	$828K	Buy	25,000 +20,000	+400%	+$752K	0.01%	927
2021 Q4	$213K	Hold	5,000	–	–	﹤0.01%	1388
2021 Q3	$222K	Sell	5,000 -19,500	-80%	-$894K	﹤0.01%	1438
2021 Q2	$1.39M	Sell	24,500 -21,000	-46%	-$1.48M	0.01%	869
2021 Q1	$3.41M	Buy	45,500 +17,000	+60%	+$1.39M	0.03%	506
2020 Q4	$2.47M	Hold	28,500	–	–	0.02%	642
2020 Q3	$1.74M	Buy	+28,500	New	+$1.44M	0.02%	623
2020 Q1	–	Sell	-108,500	Closed	-$7.83M	–	2583
2019 Q4	$7.83M	Buy	108,500 +51,200	+89%	+$6.3M	0.06%	323
2019 Q3	$8.04M	Sell	57,300 -18,700	-25%	-$3.13M	0.06%	299
2019 Q2	$13.9M	Buy	76,000 +11,700	+18%	+$2M	0.1%	151
2019 Q1	$10.2M	Buy	64,300 +10,900	+20%	+$1.58M	0.08%	203
2018 Q4	$5.12M	Buy	+53,400	New	+$6.11M	0.04%	403
2017 Q2	–	Sell	-11,200	Closed	-$796K	–	2517
2017 Q1	$796K	Buy	+11,200	New	+$656K	0.01%	1378
2016 Q3	–	Sell	-393,900	Closed	-$11.9M	–	2423
2016 Q2	$11.9M	Buy	+393,900	New	+$13.1M	0.05%	244
2015 Q3	–	Sell	-3,000	Closed	-$219K	–	2920
2015 Q2	$219K	Buy	+3,000	New	+$193K	﹤0.01%	1917

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jefferies Group's SAGE Position: Q3 2022 in Review

Jefferies Group held its Sage Therapeutics (SAGE) position steady in Q3 2022 at 9,250 shares worth $362K. The position accounts for ﹤0.01% of the portfolio, ranked #1157.

Jefferies Group first reported a position in SAGE in Q2 2016 and has held it in 19 quarters since. The position peaked at $2.62M in Q1 2019. 200 funds tracked by Wall St. Rank hold SAGE as of Q3 2022.

Jefferies Group held 9,250 shares of Sage Therapeutics worth $362K as of Q3 2022.
Jefferies Group left its Sage Therapeutics share count unchanged in Q3 2022.
Sage Therapeutics made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1157 holding.
Jefferies Group first reported a position in Sage Therapeutics in Q2 2016 and has held it in 19 quarters since.
Jefferies Group's Sage Therapeutics position peaked at $2.62M in Q1 2019.
200 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.